Biobran (rice bran arabinoxylan) supplement to support breast cancer chemotherapy
Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy
This will test whether taking 3 grams daily of Biobran for 24 weeks helps women with stage I–III breast cancer tolerate paclitaxel and doxorubicin chemotherapy and have fewer side effects.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 96 (estimated) |
| Ages | 20 Years to 65 Years |
| Sex | Female |
| Sponsor | China Medical University Hospital Academic / other |
| Drugs / interventions | chemotherapy, doxorubicin |
| Locations | 2 sites (Taichung and 1 other locations) |
| Trial ID | NCT07503496 on ClinicalTrials.gov |
What this trial studies
This interventional study enrolls 96 patients with stage I–III breast cancer at China Medical University Hospital in Taichung, Taiwan. Participants will take 3 grams of Biobran daily for 24 weeks while receiving standard paclitaxel and doxorubicin chemotherapy. Outcomes include chemotherapy-related side effects, quality of life, tumor size and tumor antigen measurements, and routine blood tests. The study compares these measures over the treatment period to characterize any supportive effects of Biobran.
Who should consider this trial
Good fit: Ideal candidates are adults with stage I–III breast cancer who are scheduled to receive paclitaxel and doxorubicin chemotherapy and are not pregnant or breastfeeding.
Not a fit: Patients with recurrent breast cancer, recent autoimmune disease, current use of plant or fungal polysaccharide supplements, pregnancy, or lactation are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, Biobran could reduce chemotherapy side effects and improve quality of life and immune-related blood markers during treatment.
How similar studies have performed: Preclinical work and small clinical reports suggest rice bran arabinoxylan has immunomodulatory and supportive effects, but strong clinical evidence for benefit during breast cancer chemotherapy is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast cancer stage I-III Exclusion Criteria: * pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements
Where this trial is running
Taichung and 1 other locations
- China Medical University Hospital — Taichung, Taiwan (Recruiting)
- China Medical University — Taichung, Taiwan (Not_yet_recruiting)
Study contacts
- Study coordinator: Chong-Kuei Lii, PhD
- Email: cklii@mail.cmu.edu.tw
- Phone: +886916226551
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.